Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Onyx Pharmaceuticals Receives FDA Accelerated Approval Of Kyprolis™ (carfilzomib) For Injection
http://www.dailymarkets.com/stock/2012/07/20/onyx-pharmaceuticals-receives-fda-accelerated-approval-of-kyprolis%E2%84%A2-carfilzomib-for-injection/
Obviously you did not get the gist of my post. I thought I was very clear on my stance that anyone could understand. Never underestimate the public.......
”He is not worthy of his name even being mentioned in my post!”
the 2 articles a POS wrote to line his own pockets
NO I wont post a link to this POS.
You answered your own question with the WEB page with no content. Did you ask yourself why?
He has organized a charity. I suspect he can’t sleep well at night these days. Imagine that.............
!Quote: We need to see a cycle break to the upside.
I feel it is in progress as of today. The upgrades do have influence on the stock. I think we break out of the 17s for the most part after today. Today was a strong move up with volume.
My area of concern is in Sept when AP113 results come to light. This and the capital gains tax issues at hand that can change at any time!
I’m more concerned with capitol gains tax at this time, than ARIADs performance!
Yes ,I live in the USA .
BuyOnDips
I agree. That and Sept is near. I dont think I will sell any shares for a while!
FDA Drug Trial Phases
http://www.nlm.nih.gov/services/ctphases.html
Looks like NAVB is on track for a high volume day. Over 300K volume in the first hour.
Im impressed with TDA responces!I think is time to change,
Post the LINK PLEASE............
I thought your last post was in line with everything I have read?
Quote
AKAPAK Share Wednesday, July 18, 2012 9:00:33 AM
Re: phillywhiz post# 2606 Post # of 2620
Analysts coverage of NAVB
Think Equity Buy $6.00
Morgan Joseph TriArtisan Buy $9.00
Rodman and Renshaw Market Outperform $7.00
WBB Securities Strong Buy $9.00
Life Tech Capital Market Outperform $5.75
Ladenburg Thalmann Buy $6.25
JMP Securities Market Outperform $8.00
Read their reports and then take you pick :)
RE: vidpok45 and ariadndndough
Done. Look at the top sticky Link.
Keep in mind Ihub only allows 4, If a new thread is stickled one will have to be removed to add the new one.
Enjoy your evening. As I stated before, I’m not arguing the point.
Hopefully this PIG can get out of the 17 STY and move into the 18 stall.
On a side note: I have a Gentleman’s bet with a good friend, that ARIA will be at $20.00 PPS by the end of 2012. Just for time reference, I made this bet about a year ago.
SKAL YO
Honestly I’m surprised some that took huge losses from the previous heydays of ARIA are not chiming in! I have read those post on occasion over the last 2 years. I;m sure you have also.
Not arguing the point. But the PPS was so low it was easy for it to drop to a penny stock when the market turned.
FACT: ARIA was a penny stock as the market classifies them.
Actually NAVB has not fully recovered from the 2 articals a POS wrote to line his own pockets about a year ago. He is not worthy of his name even being mentioned in my post! He was short and used his articles to bring the PPS down. He is no longer employed with the same company!
I have owned shares in NEOP> now NAVB for a very long time.
So, the new 52 week high is near!
lax20m
True, but your overlooking turmoil that occurred within the company. I’m sure you know what I’m speaking of.
Good post! Thats keeping it real. This company has moved so fast its sometime easy to forget how low the PPS went. Don S., not downing you in any way. You have served the members here very well and congrats for all you have done.
Member Mark scal yo
That was a brutal fall in PPS. They "the company" accounted for the fall in price due to approximately 10 units less per 2012 sales. I wonder if Senior Vice President of Sales. Ivan Delevic, MAKO's Senior Vice President of Strategic Marketing and Business Development, overstated the sales?
If he did or didn't, he was sacrificed. I’m sure the shareholders wanted a pound of flesh after losing nearly 70% in share price.
The loss in sales only accounted for about 20% less in units.
I suspect there is more to the story, but thats inside info IMHO.
I guess this PIG wants to wallow in the 17s a few more days.
Wont be long and we will see a new 52 Week High!
Maybe this PIG can stay over 18 today!
DewDiligence Share Tuesday, July 17, 2012 7:20:21 PM
Re: DewDiligence post# 145536 Post # of 145683
Clinical / Regulatory / Litigation Calendar
[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: NAVB (Lymphoseek) (AZD4694)
ABT – Bioresorbable DES: EU launch 2H12 (following reimbursement negotiations—product already approved); US launch possible in 2013 (pending clinical results).
ACHN – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75415030 .
AGN – Latisse for androgenetic alopecia: phase-2 data in men and women late 2012.
AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2012-2013 pending results of phase-3 trial in breast cancer.
AMRN – AMR101 PDUFA date 7/26/12.
BMY – Eliquis in AF: CRL issued 6/25/12; no new trials needed.
BMY – Eliquis in VTE prevention: approved in EU (3/18/11); no update on timing of possible FDA submission (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58061618 ).
ELN – Bapineuzumab: see JNJ.
BMY – Yervoy in melanoma brain mets: OS data from phase-2 ‘042’ trial 2012 (?) (RR data reported at 2010 ASCO).
BMY – Yervoy in NSCLC/SCLC: OS data from phase-2 ‘041’ trial 2012 (?) (PFS data for NSCLC reported at 2010 ASCO). Decision has been made to advance to phase-3 in NSCLC. ).
GILD – PSI-7977: numerous data reports due in 2012 (too numerous to list here). .
GILD – 4-drug phase-2 all-oral HCV trial: SVR data early 2013.
GILD – Quad PDUFA date 8/27/12 (positive FDA panel 5/11/12).
GILD – “Standalone” Evitegravir: NDA submitted 6/27/12, awaiting decision on priority review.
GILD – “Standalone” Cobicstat NDA submitted 6/28/12; MAA submitted 5/23/12.
GILD – GS-7340 (Viread enhancement): Data from phase-1b dose-ranging and phase-1 combo w Emtriva: 2Q11. (Phase-2 started 1/24/12.)
IDIX – IDX184: start of unspecified all-oral combination studies promised in PR of 6/20/12.
IDIX – IDX719 (NS5A inhibitor): 3-day PoC phase-1b monotherapy data reported 6/20/12; NVS now has exclusive option to license IDX719 with a decision expected in about 3 months.
ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.
JNJ – Xarelto NDA for VTE treatment/secondary prevention: on or about 11/2/12; (Xarelto NDA in PCI/ACS withdrawn on 7/10/12).
JNJ – Bapineuzumab: ‘301’/‘302’ (N. American) phase-3 trials conducted by JNJ: data 10/8/12 at American Neurological Assocation; (ex-US) phase-3 trials conducted by PFE: data in 2014.
LGND - Promacta NDA/MAA for HCV reviews pending (submissions made 5/30/12).
LGND - SCH527123 (MRK) CXCR2 antagonist p2 COPD is enrolled, data early 2012
MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76906028
NAVB - Lymphoseek (AZD4694) http://navidea.com/about-us/message-from-ceo.html PDUFA date Sept. 10, 2012
PFE – Tofacitinib PDUFA date Aug 2012 (positive FDA panel 5/9/12).
PFE – Xalkori (crizotinib) in NSCLC: EU decision mid 2012 (MAA accepted for review 8/17/11). Approved by FDA 8/26/11.
PFE – Bosutinib in CML: PDUFA date Oct 2012; EU decision mid 2012 (MAA accepted for review 8/17/11).
PFE – Eliquis: see BMY.
PFE – Bapineuzumab: see JNJ.
REGN – Zaltrap BLA in mCRC PDUFA date 8/4/12 (priority review).
SNTA – phase 2b ganetespib + docetaxel in NSCLC: 2Q12.
SNY – Aubagio for RRMS: PDUFA date Jun 2012; in EU, MAA accepted for review 2/23/12.
SPPI - Belinostat phase-3 data: 2012 (according to PR of 3/1/12).
TEVA – Copaxone litigation: see MNTA.
TEVA – Thrice-weekly formulation of Copaxone: timing of NDA unclear according to 6/14/12 PR announcing positive top-line results from GALA study.
VRTX – Phase-2b testing multiple (non-response-guided) protocols for Incivek + VX-222 + ribavirin in treatment-naïve genotype-1 to start 3Q12. (Data on no-IFN arms of ZENITH study reported 2/23/12.)
VRTX – Initial data on studies with ALS-2200 and ALS-2158: 2Q12.
--
Procedure for Updating Calendar
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old calendar.
2. Make your additions or modifications, inserting new items in alphabetical order.
3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).
Im looking forward to the next Q earnings. They should be stelar, this is the peak of the board walk season! Wonder what the off season numbers will look like?
Quote: More like IMDS has no active DISCLOSED promos.
The PUMP machine has a brand new engine and a full tank of High Octaine imo!
Getting ready to cross the 18 mark once again!
This should answer your question. It was the last form 4 filed by IMGG Dean sold a large number of shares over 32 million! This was in the annual report also. Speaking of annual reports, I wonder if there will be another one?
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
JANES DEAN 2. Issuer Name and Ticker or Trading Symbol
IMAGING3 INC [ IMGG ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director __ X __ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
3200 W. VALHALLA DRIVE 3. Date of Earliest Transaction (MM/DD/YYYY)
3/14/2009
(Street)
BURBANK, CA 91505
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/14/2009 (1) J (2) 32238131 (3) D (2) 27338197 (3) D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
( 1) March 14, 2009 to September 29, 2010
( 2) Mr. Janes believes that he experienced a disposition of his beneficial ownership of these shares during or after the period indicated as a result of pledging these shares as collateral for stock loans in the aggregate amount of $5,973,194 made to him from different lenders. The lenders are believed to have asserted control over and sold some or all of this collateral.
( 3) Includes 6,000,000 shares of the Company's common stock for which Mr. Janes has and continues to claim beneficial ownership, and which were erroneously omitted from the Company's last Annual Report.
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
JANES DEAN
3200 W. VALHALLA DRIVE
BURBANK, CA 91505 X X Chief Executive Officer
Signatures
/s/ Dean Janes 5/16/2012
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
LOL, No S. I remember when I traded this for .25 swing a week.
Good to see you posting BTH.
Kingfisher
Not a Pumper'
Quote Dean owes approx. 230 million.
Your numbers do not coinside with the latest SEC filings. Please recheck Deans Janes share count.
I will check the filings again tommorow also.
Have you cosidered all of the shares that have traded since the reset? Again these are not retail investors IMO. Flash stated that he thought the entire reset deal was around 200 million shares.
We are not talking about 30K total, thats just today. Its millions of $.
Eventually we will find out. But I think something is awry. IMHO
Quote
Someone buying today is hoping that when all the Cranshire shares are sold that it will go back to 0.01 and they will make 300%. There are many, many, many speculators who trade pennies like this.
If this is the case they are making a serious investment in the amount of cash they are poring into this company. Even at the current rate of .0031 if you look at the amount of shares traded since the reset.
There were over 12 million shares sold today. My question who is purchasing them? I dont think its retail investors. Something is going on here and I think we will find out at a much later date.
Any thoughts on who is purchasing these shares? Even on the big run up that IMGG had to $1.95 the day high volume was around 17 million shares that day???????
We know from the filings that Cranshire can only own less than 5% this does not exclude other companys or a sub of Cranshire.
I think its very reasonable and well thought out, but I think managment has a much differant plan in mind, we will see. Hopefully you own a very large number of shares and they will listen carefully to your suggestion.
From what I have seen in the past, Reverse splits usally turn out bad down the road.
My apolgizes for the duplicate post, computer glich.
Quote Wouldn't the next step forward in awareness be to bring the product to the masses?
They cant do this until after FDA approved! On the other hand, they can discuss trials and outcomes at places like ASCO and stay in compliance with FDA rules.
This sounds like a reverse split on the way?
http://www.sec.gov/Archives/edgar/data/1113423/000119312512302196/d372091dex991.htm
.2 Background and Reasons for the Share Consolidation
The Corporation’s Board of Directors is seeking authority to implement the Share Consolidation because it believes that the Share Consolidation may be the most effective means of avoiding a potential delisting of the Corporation’s Common Shares from The NASDAQ Global Market, on which they are currently listed and quoted for trading in the United States.
Pursuant to the requirements of NASDAQ, to remain eligible for continued listing on NASDAQ, a security must have a bid price of at least US$1.00 per share. On May 16, 2012, the Corporation received a letter from the NASDAQ Listing Qualifications Department indicating that the minimum closing bid price of the Common Shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, the Corporation was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the Rule). In accordance with NASDAQ Listing Rule 5810(C)(3)(a), the Corporation has been provided a grace period of 180 calendar days, or until November 12, 2012, to regain compliance with the Rule.
The Corporation can regain compliance with the Rule if the bid price of the Common Shares closes at US$1.00 or higher for a minimum of ten consecutive business days during the grace period, although NASDAQ may, in its discretion, require the Corporation to maintain a minimum closing bid price of at least US$1.00 per share for a period in excess of ten consecutive business days before determining that the Corporation has demonstrated the ability to maintain long-term compliance with the Rule.
If the Corporation does not regain compliance within the initial 180-day period, but otherwise meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, except for the bid price requirement, and the Corporation provides NASDAQ with notice of its intention to cure the bid price deficiency, the NASDAQ rules may permit the Corporation to transfer to The NASDAQ Capital Market, which would give the Corporation an additional 180 calendar days to regain compliance. If the Corporation is not eligible for an additional compliance period, NASDAQ will notify the Corporation that its securities are subject to delisting. At that time, the Corporation may appeal this determination to delist its securities to a Listing Qualifications Panel.
everyone always says they are not bashing but just pointing out the facts... even if thats true, i still dont understand buying a stock and then going on a public message board to crush the integrity of the company they invested their money in.. just not a smart move on anyones part... all yous are doing is turning off new investors.. your doing nothing to help the company
An investor can not help or hurt a company! A Company exsist on its own merits: Profit/ Loss and customer relations, not to mention Shareholder relations with CONZ.
Enough said.
I wait for the next filing. Im sure we will see at least 500K in sales don't you? Summer is in full swing, this was to be CONZ prime season on the NJ boardwalks.
Im sure the results will be as spectular as predictded.
: Smilin' Penny Assassin
Words and emails from the CEO means absolutely "0"!!! The reports don't lie, and the financials don't either.
Well Stated
aria2010
Maybe this is a subject that our board, as a hole should bring to IHubs attention. They are a company that changes with time, from the changes I have seen in the last 6 months. I feel they do listen to their customers, because they are a for profit company. But are slow to move as many are.
Thank you for your message,
BOD
Have you considered a Moderator position? Now is the time. I just did.
I can not make any comment one way or the other. It was deleted prior to me reading it. If you feel it was deleted unjustly, you can click on settings at the very top RT of the page, then click on my removed post, and apeal your removed post. IHub has the final say on all post. If IHub adimn deleted it, dont waste your key strokes.
Another topic
I do ask that all be very cautious in posting paitents post. Please dont use a link. We are all human and have feelings. I hope all here, have compasion for their fellow man.
BOD
Doesn't not make I morally correct.
Timed out.
This was intended to state: Doesn't make it Morally correct.
I think we should all use caution when posting any paitents comments.
Just my .02
BOD
What you fail to understand is this is IHubs SITE They Own it and are a for profit company,and moderators have very little control. IHub admin will be the final deciding factor on any post contested. Moderators are just volunteers’ assisting IHub in censoring post. Experience speaking here!
I assure you IHub could care less about any paitient…… IMHO
I do think there is a fine line on posting paitients post. I personally would never use a link to their blog.
I think we all have seen IHubs stance in the past on these post. Doesn't not make I morally correct. But it is there property along with any post we make. Keep in mind, anything posted here is on record forever.
In addition, only Ihub admin can BAN an alias from any board! So we should just drop that subject all togeather.
BOD